What is MedCap AB (publ)'s (MCAP.ST) StockRank?

MoatMap's StockRank for MedCap AB (publ) (MCAP.ST) is 61/100, with a Hold signal. This is a composite score combining Quality (71), Value (34), and Momentum (51) factor ranks across MoatMap's 20,000+ stock universe.

Does MedCap AB (publ) have an economic moat?

MedCap AB (publ) (MCAP.ST) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is MedCap AB (publ) a buy, hold, or sell?

MoatMap's current signal for MedCap AB (publ) (MCAP.ST) is Hold, based on a StockRank of 61/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is MedCap AB (publ) in?

MedCap AB (publ) (MCAP.ST) operates in the Healthcare sector, specifically the Medical Devices industry (Sweden).

Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

MCAP.ST

HOLD

MedCap AB (publ) · Healthcare · Sweden · $790M · Avg Vol: $863K/d

StockRank

Get insider-trade alerts

P/E (TTM)

38.0x

ROE

15.9%

D/E

0.3x

Dividend %

—

COMPANY DESCRIPTION

MedCap AB (publ) is a diversified healthcare company that acquires and develops specialized medical technology and life science companies, spanning diagnostics, medical devices, and specialized pharmaceuticals. MedCap's competitive advantage lies in its decentralized business model, allowing acquired companies to retain entrepreneurial drive while benefiting from strategic guidance and financial resources. It operates as a niche consolidator, building a robust portfolio in specialized healthcare segments.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	114.3M	163.2M	185.8M	216.7M	23.8%	223.7M	240.4M	260.2M	9.6%
EPS	0.81	1.19	1.44	1.51	23.0%	1.54	2.36	2.71	33.8%
Shares	14.8M	14.8M	15.0M	15.0M	+1.4%	15.0M	—	—	—
Debt	35.0M	26.9M	36.8M	49.7M	12.4%	49.2M	—	—	—
Equity	88.0M	105.2M	131.8M	149.3M	19.2%	—	—	—	—
Op CF	8.8M	23.4M	37.0M	35.2M	58.8%	34.9M	—	—	—
Inv CF	-5.8M	-15.7M	-13.2M	-40.2M	—	—	—	—	—
Fin CF	6.3M	-12.3M	-4.7M	5.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+13.2%

SMA 50SMA 200

$59.07

RSI (14)

57.6

52W High

$69.61

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

15.2%85.5

ROE

15.9%84.1

GP/Assets

49.4%87.3

Op. Margin

14.7%74.9

FCF/Assets

10.8%88.3

Piotroski

430.5

Int. Cover

10.2x60.8

D/E Ratio

0.31x41.0

Current Ratio

2.10x39.9

Value

P/E (TTM)

38.0x29.7

EV/EBITDA

18.7x33.4

P/FCF

27.4x42.4

P/B

5.6x23.3

P/S

3.9x48.4

Div Yield

—N/A

Momentum

52W High %

85%78.1

RS 6M

3%76.2

SMA 50/200

1.00x64.4

EPS Rev 4W

-5.3%8.0

EPS Rev 12W

-5.6%22.0

EPS Improve

-66%7.1

Q Growth

11%51.8

FUNDAMENTALS

Market Cap

$790M

P/E (Forward)

112.5x

Gross Margin

59.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MCAP.ST are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
MCAP.ST	MedCap AB (publ)(you)	$790M	61	HOLD
XVIVO.ST	Xvivo Perfusion AB (publ)	$838M	48	HOLD
NOLA-B.ST	Nolato AB (publ)	$1.3B	69	BUY
EKTA-B.ST	Elekta AB (publ)	$1.9B	53	HOLD
CEVI.ST	CellaVision AB (publ)	$334M	74	BUY
VITR.ST	Vitrolife AB (publ)	$1.2B	34	SELL
SECT-B.ST	Sectra AB (publ)	$5.4B	51	HOLD
BICO.ST	BICO Group AB (publ)	$117M	42	HOLD
GETI-B.ST	Getinge AB (publ)	$5.5B	86	STRONG BUY
PAX.ST	Paxman AB (publ)	$118M	34	SELL

Peer medians: ROE 4.2% · P/E 36.2x · Gross margin 62.3%

Price	$59.07
Market Cap	$790M
P/E (TTM)	38.01
P/E (Forward)	112.52
Price/Book	5.62
Return on Equity	15.9%
Return on Invested Capital	15.2%
Debt/Equity	0.31x
Gross Margin	59.2%
Operating Margin	14.7%
Revenue Growth	13.3%
Free Cash Flow	$29M